JWH 133 |
| Catalog No.GC10885 |
An Analytical Reference Standard
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 259869-55-1
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
JWH 133 is a synthetic cannabinoid (CB) that is over 200-fold selective for the peripheral CB2 receptor (Ki = 3.4 nM) over the central CB1 receptor (Ki = 677 nM).1 It inhibits the growth of tumors in mice, increasing apoptosis and impairing angiogenesis.2,3 JWH 133 also suppresses inflammation in experimental colitis and pancreatitis in mice as well as in in vitro models.4,5,6
References
1. Huffman, J.W., Liddle, J., Yu, S., et al. 3-(1',1'-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorganic & Medicinal Chemistry 7, 2905-2914 (1999).
2. Casanova, M.L., Blázquez, C., Martínez-Palacio, J., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 111(1), 43-50 (2003).
3. Blázquez, C., Casanova, M.L., Planas, A., et al. Inhibition of tumor angiogenesis by cannabinoids. The FASEB Journal 17, 529-531 (2003).
4. Kimball, E.S., Schneider, C.R., Wallace, N.H., et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. American Journal of Physiology and Gastrointestinal Liver Physiology 291(2), G364-G371 (2006).
5. Michler, T., Storr, M., Kramer, J., et al. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. American Journal of Physiology and Gastrointestinal Liver Physiology 304(2), G181-G192 (2013).
6. Ramirez, S.H., Haskó, J., Skuba, A., et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. Journal of Neuroscience 32(12), 4004-4016 (2012).
| Cas No. | 259869-55-1 | SDF | |
| Chemical Name | (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene | ||
| Canonical SMILES | CCCC(C)(C1=CC2=C([C@H]3[C@@H](CC=C(C3)C)C(C)(O2)C)C=C1)C | ||
| Formula | C22H32O | M.Wt | 312.49 |
| Solubility | 20mg/mL in ethanol, 10mg/mL in DMSO, 30mg/mL in DMF | Storage | Room temperature |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2001 mL | 16.0005 mL | 32.001 mL |
| 5 mM | 0.64 mL | 3.2001 mL | 6.4002 mL |
| 10 mM | 0.32 mL | 1.6001 mL | 3.2001 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *